Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
University of Colorado Hospital, Aschutz Inpatient Pavilion
mi
from
Aurora, CO
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
University of Colorado Hospital, Aschutz Inpatient Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Indiana University Health Neuroscience Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Beth Israel Deaconess Medical Center, Center for Life Sciences
mi
from
Boston, MA
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Beth Israel Deaconess Medical Center, Center for Life Sciences
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Wayne State University - University Health Center
mi
from
Detroit, MI
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Wayne State University - University Health Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
MS Center of Northeastern NY/Empire Neurology
mi
from
Latham, NY
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
MS Center of Northeastern NY/Empire Neurology
mi
from
Latham, NY
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
The Neurological Institute
mi
from
Charlotte, NC
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
The Neurological Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/30/2014
Swedish Medical Center
mi
from
Seattle, WA
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/30/2014
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated:  2/11/2014
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated: 2/11/2014
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated:  2/14/2014
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated: 2/14/2014
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated:  2/26/2014
Cleveland Clinic
mi
from
Cleveland, OH
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated: 2/26/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of California, Davis Medical Center
mi
from
Sacramento, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Colorado Denver
mi
from
Aurora, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
IMMUNOe
mi
from
Centennial, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
IMMUNOe
mi
from
Centennial, CO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Indiana University
mi
from
Indianapolis, IN
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Parexel International
mi
from
Baltimore, MD
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Parexel International
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
BJC Medical Group (Missouri Baptist Medical Center)
mi
from
St. Louis, MO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
BJC Medical Group (Missouri Baptist Medical Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Rhode Island Hospital
mi
from
Providence, RI
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
New Orleans Center for Clinical Research (NOCCR)
mi
from
Knoxville, TN
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
New Orleans Center for Clinical Research (NOCCR)
mi
from
Knoxville, TN
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Fletcher Allen Health Care
mi
from
Burlington, VT
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Virginia Mason Medical Center (VMMC)
mi
from
Seattle, WA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Virginia Mason Medical Center (VMMC)
mi
from
Seattle, WA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Multiple Sclerosis Center, Swedish Neuroscience Institute
mi
from
Seattle, WA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Multiple Sclerosis Center, Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities
Status: Enrolling
Updated:  4/7/2014
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities
Status: Enrolling
Updated: 4/7/2014
Mandell Center for Multiple Sclerosis at Mount Sinai Rehabilitation Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated:  7/24/2014
Alkermes Study Site
mi
from
Austin, TX
A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
Status: Enrolling
Updated: 7/24/2014
Alkermes Study Site
mi
from
Austin, TX
Click here to add this to my saved trials
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Status: Enrolling
Updated:  8/18/2014
Clinical Research Facility
mi
from
Fresno, CA
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Status: Enrolling
Updated: 8/18/2014
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Consolidation & Interference in Multiple Sclerosis
Consolidation & Interference in Multiple Sclerosis
Status: Enrolling
Updated:  10/7/2014
Kessler Foundation
mi
from
West Orange, NJ
Consolidation & Interference in Multiple Sclerosis
Consolidation & Interference in Multiple Sclerosis
Status: Enrolling
Updated: 10/7/2014
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
Status: Enrolling
Updated:  11/6/2014
Clinical Research Facility
mi
from
Evansville, IN
Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
Status: Enrolling
Updated: 11/6/2014
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes
Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes
Status: Enrolling
Updated:  11/20/2014
Kessler Foundation
mi
from
West Orange, NJ
Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes
Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes
Status: Enrolling
Updated: 11/20/2014
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Physical Telerehabilitation in Veterans With Multiple Sclerosis
Physical Telerehabilitation in Veterans With Multiple Sclerosis
Status: Enrolling
Updated:  1/20/2015
University of Maryland
mi
from
Baltimore, MD
Physical Telerehabilitation in Veterans With Multiple Sclerosis
Physical Telerehabilitation in Veterans With Multiple Sclerosis
Status: Enrolling
Updated: 1/20/2015
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Calorie Restriction in Multiple Sclerosis Patients
A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients
Status: Enrolling
Updated:  4/3/2015
Washington University in St Louis
mi
from
St Louis, MO
Calorie Restriction in Multiple Sclerosis Patients
A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients
Status: Enrolling
Updated: 4/3/2015
Washington University in St Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
Rouxbe Pilot for MS
A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis
Status: Enrolling
Updated:  4/22/2015
Oregon Health & Science University Multiple Sclerosis Center.
mi
from
Portland, OR
Rouxbe Pilot for MS
A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis
Status: Enrolling
Updated: 4/22/2015
Oregon Health & Science University Multiple Sclerosis Center.
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Tucson Clinical Site 133
mi
from
Tucson, AZ
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Tucson Clinical Site 133
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Aurora Clinical Site 132
mi
from
Aurora, CO
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Aurora Clinical Site 132
mi
from
Aurora, CO
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fort Collins Clinical Site 123
mi
from
Fort Collins, CO
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fairfield Clincial Site 110
mi
from
Fairfield, CT
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fairfield Clincial Site 110
mi
from
Fairfield, CT
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Ormond Beach Clinical Site 129
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Sarasota Clinical Site 116
mi
from
Sarasota, FL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Sarasota Clinical Site 116
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Northbrook Clinical Site 135
mi
from
Northbrook, IL
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Northbrook Clinical Site 135
mi
from
Northbrook, IL
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Fort Wayne Clinical Site 111
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Indianapolis Clinical Site 121
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated:  7/15/2015
Detroit Clinical Site 104
mi
from
Detroit, MI
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis
Status: Enrolling
Updated: 7/15/2015
Detroit Clinical Site 104
mi
from
Detroit, MI
Click here to add this to my saved trials